Evidence map›Paper›PMID 34570627›Full record

ArticleJournal of bacteriology2021

Improved growth of

Bikash Bogati, Nicholas Wadsworth, Francisco Barrera, Elizabeth M Fozo

Open access · greenAbstract read
In one paragraph

Article in Journal of bacteriology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Mechanism of action ofFrontiers in microbiology · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bikash BogatiDepartment of Microbiology, University of Tennessee, Knoxville, Tennessee.
Nicholas WadsworthDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee.
Francisco BarreraDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee.
Elizabeth M FozoDepartment of Microbiology, University of Tennessee, Knoxville, Tennessee.ORCID 0000-0002-6928-2275
University of Tennessee at Knoxville · US

Funding

Transmembrane Peptides for Targeting Acidosis - Equipment SupplementR01GM120642 · NIGMS · UNIVERSITY OF TENNESSEE KNOXVILLE · PI BARRERA, FRANCISCO NICOLAS · 2016 to 2020
$1.7M
Small proteins in sugar metabolismR15GM106291 · NIGMS · UNIVERSITY OF TENNESSEE KNOXVILLE · PI FOZO, ELIZABETH M. · 2014 to 2014
$329k
NIGMS NIH HHS R01 GM120642NIGMS NIH HHS R15 GM106291
6 · The paper itself

Abstract

Type I toxin-antitoxin systems consist of a small protein (under 60 amino acids) whose overproduction can result in cell growth stasis or death, and a small RNA that represses translation of the toxin mRNA. Despite their potential toxicity, type I toxin proteins are increasingly linked to improved survival of bacteria in stressful environments and antibiotic persistence. While the interaction of toxin mRNAs with their cognate antitoxin sRNAs in some systems are well characterized, additional translational control of many toxins and their biological roles are not well understood. Using an ectopic overexpression system, we show that the efficient translation of a chromosomally encoded type I toxin, ZorO, requires mRNA processing of its long 5' untranslated region (UTR; Δ28 UTR). The severity of ZorO induced toxicity on growth inhibition, membrane depolarization, and ATP depletion were significantly increased if expressed from the Δ28 UTR versus the full-length UTR. ZorO did not form large pores as evident via a liposomal leakage assay,

Indexed as

AntitoxinsBacterial ToxinsEscherichia coliEscherichia coli ProteinsToxin-Antitoxin SystemsAdenosine TriphosphateAminoglycosidesAnti-Bacterial AgentsBacteriaBacterial ProteinsKanamycinRNARNA, MessengerAdenosine TriphosphateAminoglycosidesAnti-Bacterial AgentsAntitoxinsBacterial ProteinsBacterial ToxinsEscherichia coli ProteinsKanamycinRNARNA, MessengerZorO protein, E coli

Identifiers

PMID34570627
PMCPMC8765423
OpenAlexW3203577813

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.